Why does chronic kidney disease commonly cause anemia?
Choose an answer, then check it.
Clinical Pharmacology · Lipid and Blood Disorder Medications
Erythropoiesis-Stimulating Agents
On this page 6 sections
In 30 seconds
Erythropoiesis-stimulating agents (ESAs) mimic erythropoietin, the kidney hormone that signals bone marrow to make red blood cells, treating anemia from chronic kidney disease, chemotherapy, zidovudine therapy, and select surgeries. The key safety lesson: pushing hemoglobin toward normal with ESAs raises the risk of death, stroke, heart attack, blood clots, and faster tumor growth in some cancers, so clinicians use the lowest dose that avoids transfusion, not one that normalizes hemoglobin.
The college version
Why the kidney matters
Healthy kidneys sense low oxygen delivery and secrete erythropoietin, signaling bone marrow to produce red blood cells. In chronic kidney disease, damaged renal tissue cannot make enough erythropoietin, so anemia develops even with adequate iron and nutrients — unlike anemia from iron, B12, or folate deficiency, where the raw materials themselves are missing.
The drugs
Epoetin alfa is recombinant human erythropoietin, dosed frequently. Darbepoetin alfa's extra sugar chains slow clearance, giving a longer half-life and less frequent dosing; both bind the same erythropoietin receptor on marrow progenitor cells. Oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) instead stabilize a transcription factor that boosts the body's own erythropoietin production, an oral alternative for some kidney-related anemia.
Indications
ESAs treat anemia of chronic kidney disease, chemotherapy-induced anemia in certain cancers, zidovudine-associated anemia in HIV infection, and reduced transfusion need in selected elective surgery patients.
The central safety story
Trials targeting normal or near-normal hemoglobin showed increased death, myocardial infarction, stroke, and venous thromboembolism versus conservative targets, and in some cancers faster tumor progression. ESAs therefore carry boxed warnings directing the lowest dose that avoids transfusion, not correction to normal hemoglobin — the goal is symptom relief, not normalization.
Iron, timing, and monitoring
ESAs only work if marrow has enough iron, so iron studies are checked before and during therapy and deficient stores replaced — an iron-deficient marrow responds poorly even to higher doses. Response is not immediate; a meaningful rise takes weeks, so dosing is adjusted on trends, not single readings. Hypertension is a common adverse effect from increased blood viscosity, so pressure is monitored and controlled before starting. Rarely, pure red cell aplasia occurs: antibodies against erythropoietin nearly halt production, requiring the ESA to be stopped.
Nursing considerations
Check blood pressure at each visit, never shake the vial (agitation denatures the protein), confirm adequate iron studies, and track hemoglobin trends rather than one value.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Your kidneys are like a manager who notices the body is low on delivery trucks (red blood cells) and radios the bone marrow factory to build more. If the manager gets sick, the message stops and trucks run low — that's anemia from kidney disease. ESA medicines act like a walkie-talkie sending the "build more trucks" message. But asking for too many trucks jams the roads, so doctors ask for just enough to keep deliveries smooth.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient starting epoetin alfa for chemotherapy-induced anemia has low ferritin and low transferrin saturation. Why should this be addressed during ESA therapy?
Show answer
Low iron stores should be corrected because ESAs need iron as raw material to build new red blood cells.
Without adequate iron, marrow cannot respond well to the erythropoietin signal, so the medication seems ineffective despite proper dosing.
A nurse notices a patient's blood pressure has risen steadily since starting an ESA. What should the nurse do, and why does this matter with this drug class?
Show answer
Notify the prescriber and continue close blood pressure monitoring, since hypertension is a common, expected adverse effect of ESA therapy.
Catching a rising trend early allows dose or blood pressure adjustment before complications like stroke occur.
Quick check
3 questions here. Answers stay hidden until you check.
What is the main advantage of darbepoetin alfa over epoetin alfa?
Choose an answer, then check it.
Why do ESA boxed warnings direct clinicians to avoid targeting a normal hemoglobin level?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.